Zai Lab Limited announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for margetuximab, an investigational, Fc-engineered monoclonal antibody that targets HER2.
[Zai Lab Limited]
Sorry, but the selected Zotpress account can't be found.